You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the P…

Article Text

Article menu
Download PDFPDF
Oral Communication 1 – Gynaecological Cancer
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
  1. K Moore1,
  2. N Colombo2,
  3. G Scambia3,
  4. B-G Kim4,
  5. A Oaknin5,
  6. M Friedlander6,
  7. A Lisyanskaya7,
  8. A Floquet8,9,
  9. A Leary9,10,
  10. GS Sonke11,
  11. C Gourley12,
  12. S Banerjee13,
  13. A Oza14,
  14. A González-Martín15,
  15. C Aghajanian16,
  16. W Bradley17,
  17. C Mathews18,
  18. J Liu19,
  19. ES Lowe20,
  20. R Bloomfield21 and
  21. P DiSilvestro18
  1. 1Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA
  2. 2University of Milan-Bicocca and IEO European Institute of Oncology IRCCS, Milan
  3. 3Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica, Rome, Italy
  4. 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  5. 5Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  6. 6University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia
  7. 7St Petersburg City Oncology Dispensary, St Petersburg, Russian Federation
  8. 8Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
  9. 9Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Paris
  10. 10Gustave-Roussy Cancer Campus, Villejuif, France
  11. 11The Netherlands Cancer Institute, Amsterdam, The Netherlands
  12. 12Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh
  13. 13The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
  14. 14Princess Margaret Cancer Centre, Toronto, ON, Canada
  15. 15Clínica Universidad de Navarra, Madrid, Spain
  16. 16Memorial Sloan Kettering Cancer Center, New York, NY
  17. 17Froedtert and the Medical College of Wisconsin, Milwaukee, WI
  18. 18Women and Infants Hospital, Providence, RI
  19. 19Dana-Farber Cancer Institute, Boston, MA
  20. 20AstraZeneca, Gaithersburg, MD, USA
  21. 21AstraZeneca, Cambridge, UK

Abstract

Introduction/Background In SOLO1 (NCT01844986; GOG-3004), maintenance olaparib significantly improved progression-free survival (PFS) vs placebo (HR 0.30; 95% CI 0.23–0.41; P<0.0001; Moore et al. NEJM 2018) in patients with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who were in clinical complete response (CR) or partial response (PR) following platinum-based chemotherapy. This analysis evaluates olaparib efficacy in SOLO1 by timing of surgery and presence of residual tumour following surgery.

Methodology SOLO1 recruited patients who had undergone upfront or interval cytoreductive surgery and had no residual or residual macroscopic disease. Patients were stratified by platinum response (clinical CR or PR) and received olaparib tablets 300 mg twice daily or placebo. PFS was assessed by investigators using modified RECIST v1.1.

Results 260 patients were randomized to olaparib and 131 to placebo; one patient did not receive placebo. Median follow-up was 41 months in both arms. 63% and 35% of patients underwent upfront and interval surgery, respectively; 76% and 21% had no residual and residual macroscopic disease, respectively, after surgery regardless of timing; and 44% of SOLO1 patients had stage III disease, underwent upfront surgery and had no residual disease following surgery. PFS was significantly improved with olaparib, regardless of the timing of surgery or residual disease status after surgery (table 1). PFS was also significantly improved in the subgroup of patients with stage III disease who underwent upfront surgery and had no residual disease following surgery.

Abstract – Table 1
Abstract – Table 1

Any grade and grade ≥3 TEAEs

Abstract – Figure 1
Abstract – Figure 1

TEAE Summary

Conclusion Maintenance olaparib improved outcomes compared with placebo in patients with newly diagnosed advanced OC and a BRCAm, regardless of the timing of surgery or residual disease status after surgery. Olaparib improved PFS in stage III patients who had undergone upfront surgery and had no residual disease, a population at high risk of progression, but typically excluded from first-line OC trials.

Disclosure KM: Ad board: AZ, Advaxis, Clovis, Tesaro, Genentech/Roche, Immunogen, VBL Therapeutics, Merck, Janssen, Aravive, Pfizer, Eisai, Samumed, Oncomed. NC: Honoraria/reimbursement, speaker role/advisory board fees: AZ, Roche, Tesaro, PharmaMar; advisory board fees: Clovis, Pfizer. GS: None. B-GK: None. AO: Consulting fees: Roche, AZ, PharmaMar, Clovis, Tesaro, Immunogen, Genmab. MF: Honoraria, speaker role/advisory boards: AZ; advisory board fees: MSD, Lilly, Takeda; non-comp consulting: AbbVie. AL: None. AF: Advisory board fees: AZ, Clovis; congress support: Roche, PharmaMar; advisory board fees/congress support: Tesaro. AL: Honoraria/reimbursement, advisory board fees: AZ; advisory board fees: Clovis, Biocad; consulting fees: Seattle Genetics. GS: Research funding: AZ, Merck, Novartis, Roche. CG: Honoraria/reimbursement, consulting fees, grants: AZ, Tesaro, Nucana; honoraria/reimbursement, consulting fees: Roche, Clovis, Foundation One, MSD, Sierra Oncology; grants: Novartis, Aprea. SB: Grants, honoraria/reimbursement: AZ; honoraria/reimbursement: Tesaro, Clovis, Merck, PharmaMar, Roche, Seattle Genetics. AO: Steering committee role (non-comp): AZ, Clovis, Tesaro. AG-M: Speaker role/consulting fees: AZ, Tesaro, PharmaMar, Roche; consulting fees: Clovis, Inmunogen, Genmab, Pfizer, MSD. CA: Honoraria/reimbursement: Tesaro, ImmunoGen, Clovis. WB: None. CM: None. JL: Advisory board fees: AZ, Clovis, Mersana, Tesaro. ESL: Shareholder, employee: AZ. RB: Shareholder, employee: AZ. PD: Consulting fees: AZ, Tesaro.

http://dx.doi.org/10.1136/ijgc-2019-ESGO.17

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.